Giuliari GP, Sadaka A, Hinkle DM. Biologic agents in experimental autoimmune uveitis.
Int Ophthalmol 2013;
34:145-56. [PMID:
23494482 DOI:
10.1007/s10792-013-9756-0]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2013] [Accepted: 03/04/2013] [Indexed: 12/18/2022]
Abstract
Experimental uveitis models were developed in an effort to elucidate the pathogenesis of human uveitis. The therapeutic effects of numerous anti-inflammatory agents including corticosteroids and immunomodulatory agents including biologic response modifiers have been investigated in both experimental and human uveitis. Monoclonal antibodies to tumor necrosis factor alpha and anti-interleukins, among others, demonstrate efficacy and are employed in the treatment of uveitis refractory to conventional immunomodulatory agents.
Collapse